EOLS News and Press, Evolus Inc. From 11/02/21

Evolus (NASDAQ:EOLS) began a clinical program to study an “extra strength” dose for extended duration of Jeuveau (prabotulinumtoxinA-xvfs) its flagship neurotoxin product for aesthetics. Our proven clinical development team has initiated Phase II study preparation, and we l...

Evolus (NASDAQ:EOLS): Q3 GAAP EPS of -$0.35 beats by $0.01. Revenue of $26.68M beats by $1.27M. Press Release Gross profit margin and adjusted gross profit margin were 54.2% and 56.9%, respectively. For further details see: Evolus EPS beats by $0.01, beats on revenue

Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-End Initiated Jeuveau ® “Extra Strength” Phase II Clinical Program to Demonstrate Extended Duration NEWPORT BEACH,...

Program Designed to Offer Consumers an “Extra Strength” Dosing Option Evolus is Uniquely Positioned to Capitalize on this Opportunity with the Company’s Aesthetics-Only Strategy and Jeuveau ® Product Precision First Patient Enr...

NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Re...

Evolus (NASDAQ:EOLS) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $25.41M Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. Revenue estimat...

OTCQX:ACDVF,AHH,AME,APO,OTCQX:ARBKF,ARCB,ARNC,AROC,AVNS,BCC,BHC,BLD,BLMN,BP,CEIX,CEN,CMI,COP,CRSR,CTLT,DD,DEA,EL,EOLS,EPD,ESPR,ETN,ETRN,EXTR,FMS,OTCPK:FSNUF,GLDD,GLYC,GNRC,GPN,HEP,HSIC,IAA,IART,IDXX,IEP,INCY,INGR,IPGP,IT,KKR,KOPN,LCII,LDOS,LEA,LGIH,LPX,MGY,MIME,MLM,MMP,MPC,MPLX,MYGN,OTCQB:NLS...

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a bu...

It has been more than half a year since we last took a look at a Busted IPO named Evolus. The company has had a couple of quarterly earnings results posted since our last analysis. We update our investment analysis around Evolus in the paragraphs below. For further details s...

NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in...